Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743661 · ClinicalTrials.gov registry record · Phase 2
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
A Phase 2 study of Recurrent Medulloblastoma and Recurrent Ependymoma, sponsored by Pediatric Brain Tumor Consortium.
- Active
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT04743661 is a Phase 2 study of Recurrent Medulloblastoma and Recurrent Ependymoma that is active but no longer recruiting, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 62 participants, above the 38-participant average among 12 other Recurrent Medulloblastoma trials with a reported enrollment target (63% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT04743661, a Phase 2 study of Recurrent Medulloblastoma and Recurrent Ependymoma, is active but no longer recruiting, sponsored by Pediatric Brain Tumor Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Omburtamab I-131
- DRUG Liothyronine
Study Locations (3)
California
- Children's Hospital Los Angeles - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743661
The ClinicalTrials.gov registry entry for NCT04743661 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 12 other Recurrent Medulloblastoma trials with a reported enrollment target (63% higher). The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Medulloblastoma appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04743661 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04743661 about?
NCT04743661 is a clinical study titled "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma". A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direc...
What is the current status of trial NCT04743661?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-04-04. Estimated completion is 2027-09-30.
What conditions does trial NCT04743661 study?
This clinical trial studies the following conditions: Recurrent Medulloblastoma, Recurrent Ependymoma.
What interventions are being tested in trial NCT04743661?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Irinotecan (DRUG), Omburtamab I-131 (DRUG), Liothyronine (DRUG).
Who is sponsoring clinical trial NCT04743661?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743661 being conducted?
This trial has 3 study locations across California, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
COMPLETED · Phase 2
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.